Vera Therapeutics, Inc.
Viela Bio, Inc. (NASDAQ: VIE) is a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's lead product candidate, atacicept, is a native human TACI-Fc fusion protein that binds both B-cell activating… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Vera Therapeutics, Inc. does
In the company’s own words
Viela Bio, Inc. (NASDAQ: VIE) is a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's lead product candidate, atacicept, is a native human TACI-Fc fusion protein that binds both B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL) cytokines and is self-administered subcutaneously at home. Atacicept is currently being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases. The company submitted a Biologics License Application for atacicept in IgAN to the FDA in November 2025, which received priority review with a PDUFA target action date of July 7, 2026.
Beyond its lead indication, Viela Bio holds worldwide exclusive development and commercial rights to MAU868, a potentially first-in-class monoclonal antibody to treat reactivated BK virus infections in kidney transplant recipients, for which the company completed a Phase 2 clinical trial in 2022. In January 2025, the company acquired worldwide exclusive development and commercial rights to VT-109, a novel next-generation dual BAFF/APRIL inhibitor in preclinical development with potential applications across multiple B-cell-mediated diseases.
The company's strategy centers on developing disease-modifying medicines that target the source of immunological disease while minimizing side effects compared to current standard-of-care treatments like systemic steroids. Viela Bio's research and development and commercial teams are led by experienced drug development executives with proven track records in clinical and commercial development who have been involved in the approvals of more than 15 medicines from leading companies including Gilead Sciences and Amgen.
The company estimates the global market opportunity for novel disease-modifying therapeutics in IgAN alone at approximately six to ten billion dollars annually. Viela Bio operates with a gated-capital raise approach, scaling product candidate investment in close step with key development milestones. The company's website is www.vielabio.com.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- BRISBANE, CA
- Fiscal year end
- December
- CIK
- 1831828
- SIC
- 2834
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Vera Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Vera Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Vera Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Vera Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Vera Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”